// App-Quantinova.ai

EP1306 : BENEFIT OF CONTINUING THERAPY WITH LUSPATERCEPT IN PATIENTS WITH BETA-THALASSEMIA WHO DO NOT ACHIEVE ≥33% REDUCTION IN RED BLOOD CELL (RBC) TRANSFUSION BURDEN (TB) IN WEEKS 13–24 IN THE BELIEVE TRIAL

Researchers

Presenter

  • Antonio Piga

Principal Investigators

  • Maria Domenica Cappellini

  • John B. Porter

  • Olivier Hermine

  • Kevin H. M. Kuo

  • Thomas D. Coates

  • Antonis Kattamis

  • Farrukh Shah

  • Abderrahim Khelif

  • Yesim Aydinok

  • George Zhang

  • Jeevan K. Shetty

  • Dimana Miteva

  • Tatiana Zinger

  • Aylin Yucel

  • Derek Tang

  • Ali T. Taher

Medical Centers

  • Department of Pediatric Hematology, Ege University Hospital, Izmir, Turkey

  • USC Keck School of Medicine, Los Angeles, United States

  • University of Turin, Turin, Italy

  • Fondazione IRCCS Ca' Granda Maggiore Hospital, University of Milan, Milan, Italy

  • Department of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon

  • First Department of Radiology, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece

  • Department of Haematology, Tenon University Hospital, Assistance Publique Hopitaux de Paris, Paris, France

  • University College London, University College London Hospitals, LONDON, United Kingdom

  • Division of Medical Oncology and Hematology, Department of Medicine, University Health Network, Division of Hematology, Department of Medicine, University of Toronto,Toronto, ON,Canada

  • Department of Microbiology, Whittington Health NHS Trust, London, United Kingdom

  • Bristol Myers Squibb, Princeton, New Jersey, United States

  • Farhat Hached Teaching Hospital, Sousse University,Sousse,Tunisie

  • Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

  • Imagine Institute, INSERM U1163, University of Paris, Paris, France

Locations

  • Turkey

  • United States

  • Italy

  • Lebanon

  • Greece

  • France

  • United Kingdom

  • Canada

  • Tunisia

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Genetic Disorder

  • Ophthalmology (OP)

  • Endocrine/metabolic Diseases (ME)

Disease

  • Beta-thalassemia

  • Hemochromatosis

  • Thalassemia

Biomarkers

  • Red Blood Cells

Drug/Treatment

  • luspatercept

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02604433

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved